KRAS and non-small cell lung carcinoma: Here, using two non-small cell lung carcinoma (NSCLC) cell lines, one harboring a fast-cycling KRAS mutation and one with wildtype RAS, we show that RASSF1A suppression downregulates DAB2IP.